Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1644
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18193062 | CANCER TREATMENT COMBINATIONS | Non-Final OA | The Regents of the University of California |
| 18095467 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17356497 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18061824 | COMBINATION THERAPIES | Non-Final OA | Novartis AG |
| 17733303 | IL-1 Binding Proteins | Final Rejection | AbbVie Inc. |
| 17769917 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT USING NANOPARTICLES CONJUGATED WITH MULTIPLE LIGANDS FOR BINDING RECEPTORS ON NK CELLS | Non-Final OA | The University of North Carolina at Chapel Hill |
| 17271108 | COMBINATION THERAPY | Final Rejection | MEDIMMUNE LIMITED |
| 17887828 | UBIQUITIN LIGASE KPC1 PROMOTES PROCESSING OF P105 NF-KAPPAB1 TO P50, ELICITING STRONG TUMOR SUPPRESSION | Final Rejection | Technion Research & Development Foundation Limited. |
| 18842400 | GENETICALLY ENGINEERED PLACENTAL MUCOSALASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF | Final Rejection | PLURI BIOTECH LTD. |
| 18039369 | CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION | Non-Final OA | CORNELL UNIVERSITY |
| 17799193 | HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 17255949 | PERSONALIZED CANCER VACCINE EPITOPE SELECTION | Final Rejection | ModernaTX, Inc. |
| 18250150 | NOVEL TRIPLE AGONIST HAVING ACTIVITIES ON ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS AND USE THEREOF | Non-Final OA | HANMI PHARM. CO., LTD |
| 17434573 | CANCER THERAPY USING 3,5-DISUBSTITUTED BENZENE ALKYNYL COMPOUND AND IMMUNE CHECKPOINT INHIBITOR | Final Rejection | TAIHO PHARMACEUTICAL CO., LTD. |
| 18154091 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS | Non-Final OA | Immatics Biotechnologies GmbH |
| 18154098 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS | Non-Final OA | Immatics Biotechnologies GmbH |
| 18174015 | Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients | Final Rejection | THE SCRIPPS RESEARCH INSTITUTE |
| 18188380 | METHODS AND COMPOSITIONS FOR DOSING IN ADOPTIVE CELL THERAPY | Non-Final OA | Juno Therapeutics, Inc. |
| 18548803 | LYMPHANGIOGENESIS PROMOTING FACTOR-EXPRESSING FIBROBLAST, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Non-Final OA | METCELA INC. |
| 17859861 | SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY | Final Rejection | The United States of America, as represented by the Secretary, Department of Health and Human |
| 17581706 | PLATELET-FACILITATED DELIVERY OF THERAPEUTIC COMPOUNDS | Final Rejection | CSTS Health Care Inc. |
| 18165623 | COMPOSITIONS AND METHODS FOR TREATING EGFR POSITIVE CANCERS | Non-Final OA | A2 Biotherapeutics, Inc. |
| 18182165 | METHODS OF TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA USING TELISOTUZUMMAB VEDOTIN AND OSIMERTINIB | Non-Final OA | ABBVIE MANUFACTURING MANAGEMENT UNLIMITED COMPANY |
| 18180998 | PRODRUGGABLE ANTIBODIES, PRODRUGS THEREOF, AND METHODS OF USE AND MAKING | Non-Final OA | BRISTOL -MYERS SQUIBB COMPANY |
| 18178778 | PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCER | Non-Final OA | APEIRON BIOLOGICS GMBH |
| 18175427 | ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) | Final Rejection | Epic Sciences, Inc. |
| 17584892 | MULTISPECIFIC AND MULTIFUNCTIONAL MOLECULES AND USES THEREOF | Final Rejection | Marengo Therapeutics, Inc. |
| 17615748 | ANTIBODY CLEAVAGE SITE BINDING MOLECULE | Final Rejection | Yamaguchi University |
| 17426813 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | Non-Final OA | Hangzhou DAC Biotech Co., Ltd. |
| 17820913 | CONDITIONALLY ACTIVE POLYPEPTIDES | Non-Final OA | BioAtla, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy